Pasithea Therapeutics eyes IND filing for MEK1/2 inhibitor PAS-004 following FDA guidance
Nov. 30, 2023
Pasithea Therapeutics Corp. has received written responses from the FDA to questions submitted for a type 2 pre-IND meeting regarding the clinical development plan for PAS-004 (CIP-137401).